• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    1403900 Oral compositions CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT 2 Nov 1972 [8 Nov 1971] 50495/72 Heading A5B An oral pharmaceutical composition for the prevention or relief of renal calculi comprises as active ingredients at least one magnesium ion source, at least one citrate ion source and vitamin B 6 , the magnesium ion source and the citrate ion source being in the proportions of 2-20% and 66-98.5% respectively based on the weight of active ingredients, and optionally solid or liquid pharmaceutical carriers or diluents.
    公开号:SU1009467A1
    申请号:SU721846969
    申请日:1972-11-04
    公开日:1983-04-07
    发明作者:Немеш Иозеф；Себени Рудольф；Береньи Михаль；Франг Деже；Маршо Миклош；Гал Дьюла
    申请人:Хиноин Дьедьсер -Еш Ведьесети Термекек Дьяра Рт (Инопредприятие)；
    IPC主号:
    专利说明:

    with
    4 Ot) vj The invention relates to the field of medicine and relates to a means for dissolving stones formed in the kidneys. . An agent for dissolving urinary stones, containing citric acid salt and sugar IJ, has been found known. However, the known agent is impossible. can be used by patients with diabetes mellitus. A means is known for dissolving urinary stones, containing sodium citrate, potassium, citric acid and fillers 2. However, the known agent does not effectively dissolve calculi containing uric acid and calcium oxalate, and re-formation of stones is possible. The aim of the invention is to dissolve stones containing urine acid and calcium oxides and prevent the re-formation of stones. The goal is achieved by the fact that the means for dissolving urinary calculi containing sodium citrate, potassium, or monoacid and excipients, additionally contains magnesium citrate, and hydrogen chloride pyridoxine with the following component ratio, weight,%: sodium citrate 10 -40 Potassium citrate. 20-40 Citric acid 0.1-30 Magnesium citrate 2-20 Hydrochloric. pyridoxine 0.01-1.5 Fillers Else. The proposed agent contains citric acid, citric acid salt, formed by alkali metal (e.g., citrate of potassium or sodium citrate) or citrate acid, formed from alkaline earth metal (for example, calcium citrate) as a source of citrate ions. An organic or inorganic magnesium salt (preferably magnesium oxide, magnesium acetate or magnesium carbonate) can be used as a source of ibnov magnesium. As a joint source of citrate and magnesium ions, magnesium citrate can be used. Alkali metal citrate may also be provided in the medium by simultaneous use of citric acid and alkali metal carbonate or alkali metal bicarbonate. The urinary calculus agent may be in solid form (tablets, dragee, granules, powder mixtures) or in liquid form (e.g., solution, suspension, emulsion). Granules are the best form to consume. The product contains magnesium citrate, citric acid, trisodium citrate, tricalcium citrate, pyridoxine in the form of hydrochloric salt Metotsel 60 Hg and Ariavit mouth 9.92. In the case of oral administration, it is desirable that a therapeutic dose of the drug be 10 g per cyt. The amounts of active ingredients used in the agent can vary widely depending on the requirements of each individual case (patient condition, type of stones formed in the kidneys). The agent may also contain vitamin B, which eliminates the blocking of glyoxalate. The agent also contains inert, non-toxic, solid or liquid substances that are diluents or carriers. For this purpose, for example, sodium carbonate, calcium carbonate, water starch are used. The drug may also contain dyes. The agent can be prepared by any known method used in the drug manufacturing technology. In the preparation of the granulated agent, the constituents are sieved, then thoroughly mixed together until a completely homogeneous mass is obtained, and then granulated using de-ionized water. The granulated preparation thus obtained is dried to the desired moisture content. Drops are prepared by applying a protective coating to the granulated preparation, when using a powder mixture, it is dissolved before it is taken in water. The invention is illustrated by the following examples. Example 1. A granulated preparation of the following composition is prepared, g: Pyridoxine in the form of a hydrochloric acid salt 0.40 Magnesium citrate 9.00 Citric acid 13.5 Trisodium citrate 36.16 Trikali citrate 39.7 Metotsel 60 Hg 1, 23 Ariawayt Roth .9.92 0.01 The above components are sieved, mixed thoroughly until they are homogeneous, and then granulated using water that does not contain ions. The granulated product is dried in a drying apparatus to a lag content of 1-1.5%. The compaction is determined by drying at a temperature of 80 ° C until constant weight is reached.
    The granulated product is coated with a coating at a temperature of 40 ° C in a drum dA when drafting when air is blown using the following composition:
    Metocel 60 Hg, g 3.00 Ariavit-mouth, g 0 01 Anhydrous ethanol, ml 50.00 Methylene chloride, ml 50.00 400 ml of the liquid used for coating are applied per 1 kg of granulated product. Granules obtained in this way disintegrate in water at a temperature of 5 minutes.
    Example 2. A granulated product of the following composition is prepared by a known method of preparing drugs; mg;
    Sodium citrate. 4,0 Potassium citrate Lemon-acid as monohydrate 1,5
    Pyridoxine in the form of soloxys5 salt of salt 0.05 Magnesium citrate 1.0 Pp and me R 3. A granular product of the following composition is prepared by a known method for the preparation of drugs, mg:
    Sodium citrate 485 Lemon acid as monohydrate820
    Magnesia oxide 100
    Potassium bicarbonate 400 Pyridoxine in the form of chloris-. ferric salt5
    Example 4. The following constituents are dissolved in water, mg: Sodium citrate 485 Potassium citrate 420. Citric acid monohydrate 550
    0
    Pyridoxine as Chloe. hydrostate salt 5 magnesium oxide 100
    The proposed remedy does not have a toxic effect even with prolonged use, the federation is used to dissolve urinary stones (in 36 cases).
    20 stones, including from the bottom-, 2-3 cm, for; 2-3 months have healed {1 and completely dissolved (on
    0 radiographs, the shadow of the stone disappeared), complaints of patients stopped. 13 stones decreased in size and 3-5 weeks, in 3 patients insolubility was caused by the presence of magnesium phosphate 5 ammonium and apatite carbonate, which were deposited on the stones as a layer.
    The proposed agent effectively dissolves calculi containing uric acid and calcium oxalate,
    0 and prevents the re-formation of stones.
    权利要求:
    Claims (1)
    [1]
    Means for dissolving urinary calculi containing sodium citrate, potassium citrate, citric acid and excipients, characterized in that, in order to dissolve calculi containing uric acid and calcium oxalate, and prevent re-formation of stones, it additionally contains magnesium citrate and hydrochloride pyridoxine in the following quantitative ratio of components, wt.%: Sodium citrate Potassium citrate Citric acid Magnesium citrate Hydrochloride pyridoxine Fillers
    10-40
    20-40
    0.1-30 2-20
    0.01-1.5
    The rest of the laziness are granules. The product contains magnesium citrate, citric acid, trisodium citrate, tricalodium citrate, pyridoxine in the form of the hydrochloride salt Metocel 60 Hg and Ariavit-mouth 9.92.
    In the case of oral administration, it is desirable that the therapeutic dose of the drug is 10 g per day. The amounts of active active substances used in the product can vary widely depending on the requirements for each individual case (patient's condition, type of kidney stones).
    The product may also contain vitamin B &, which eliminates the blocking of glyoxalate.
    The product also contains inert, non-toxic, solid or liquid substances, which are diluents or carriers. For this purpose, use, for example, talc, calcium carbonate, starch, water. The drug may also contain dyes.
    The tool can be prepared by any known method used in the manufacture of medicines. When preparing a granular product, the components are sieved, then carefully changed. sew together to obtain a completely homogeneous mass and then granulate using de-ionized water. The granular preparation obtained in this way is dried to the desired moisture content.
    Dragees are prepared by applying a protective coating to a granular preparation, when using a powder mixture, it is dissolved before use in water.
    The invention is illustrated by the following examples.
    Example 1. A granular preparation of the following composition is prepared ; va, g:
    类似技术:
    公开号 | 公开日 | 专利标题
    US5211958A|1993-05-18|Pharmaceutical composition and process for its preparation
    SU1443788A3|1988-12-07|Method of producing solid medicine
    US6555133B2|2003-04-29|Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
    KR960009182B1|1996-07-16|Pharmaceutical tablet and granulate and process for their preparation
    JP2907299B2|1999-06-21|Pharmaceutical preparations that bind stomach acid
    US4309408A|1982-01-05|Effervescent powders
    CA1040532A|1978-10-17|Process for producing solid bismuth-containing pharmaceutical compositions
    EA001537B1|2001-04-23|Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a great amount of medicaments
    EA002331B1|2002-04-25|Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
    JPH05112445A|1993-05-07|Transfer system that hastens initiation of action and increases latent characteristics
    PL200957B1|2009-02-27|Celecoxib compositions and the use thereof
    NZ201008A|1985-11-08|Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient
    US5397574A|1995-03-14|Controlled release potassium dosage form
    KR19980702370A|1998-07-15|Pharmaceutical compositions stabilized with basic substances
    JP4395338B2|2010-01-06|Pharmaceutical composition having antibiotic activity
    BG64348B1|2004-11-30|Paracetamol-containing tablet medicamentous form for swallowing
    SU1009467A1|1983-04-07|Agent for dissoluting urine concretions
    US3865935A|1975-02-11|Tableting of erythromycin base
    US4601895A|1986-07-22|Delayed-action acetylsalicylic acid formulations for oral administration
    US4190655A|1980-02-26|Amiloride citrate
    CA1182049A|1985-02-05|Apap antacid composition
    RU2240784C1|2004-11-27|Arbidol-base medicinal agent
    ES2248850T3|2006-03-16|PHARMACEUTICAL FORMULATIONS CONTAINING SALTS OF POTASIOM SODIUM AND TRIS OF OXAPROZIN.
    EP0319074B1|1992-01-29|Pharmaceutical composition and process for its preparation
    BG60901B1|1996-06-28|Granulate containing sodium 2-mercaptoethanesulphonate as active substance and method for its preparation
    同族专利:
    公开号 | 公开日
    GB1403900A|1975-08-28|
    DD100631A1|1973-10-05|
    HU165181B|1974-07-27|
    IL40685D0|1972-12-29|
    IL40685A|1976-08-31|
    CA978479A|1975-11-25|
    ATA925372A|1976-01-15|
    DE2252665A1|1973-05-10|
    AT332531B|1976-10-11|
    DE2252665C2|1987-09-10|
    CS217603B1|1983-01-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3328304A|1964-07-31|1967-06-27|Guardian Chemical Corp|Chelating agents and methods for their manufacture|
    FR2019261B1|1969-03-19|1978-08-18|Sauba Lab|DE3046580A1|1980-12-11|1982-07-01|Leskovar, Peter, Dr.-Ing., 8000 München|Prophylactic and curative treatment of urinary calculi - by admin. of organic acid, dye, metal oxide, etc.|
    DE3728814A1|1987-08-28|1989-03-30|Lentia Gmbh|SOLUTION FOR USE AS A RINSING LIQUID IN THE DESTRUCTION OF NON-BODY DEPOSITS IN HUMAN AND ANIMAL TISSUES OR BODIES|
    JP2545479B2|1989-02-07|1996-10-16|ミッションファーマカルカンパニー，インコーポレーテッド|Pharmaceutical composition|
    CA1326040C|1989-11-16|1994-01-11|Neill B. Walsdorf|Magnesium-potassium citrate|
    DE4409949C2|1994-03-23|1996-11-21|Madaus Ag|Use of calcium alkali citrates for the prophylaxis and treatment of degenerative diseases of the bone structure|
    DE10028167B4|2000-06-09|2004-02-19|Storch, Rüdiger, Dr.|Use of calcium salts to counteract the formation of oxalate stones|
    US8603989B2|2008-05-22|2013-12-10|Bristol-Myers Squibb Company|Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same|
    FR2967576B1|2010-11-18|2013-07-12|Advicenne Pharma|PHARMACEUTICAL COMPOSITION COMPRISING KREBS CYCLE PRECURSOR SALT, IN PARTICULAR CITRATE SALT, AND ITS USE AS A MEDICINAL PRODUCT|
    FR2967578B1|2010-11-18|2012-12-28|Advicenne Pharma|PHARMACEUTICAL COMPOSITION COMPRISING CITRATE AND BICARBONATE SALTS AND USE THEREOF FOR THE TREATMENT OF CYSTINURIA|
    WO2014152789A1|2013-03-15|2014-09-25|New York University|Citrate containing beverage|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HUCI001185|HU165181B|1971-11-08|1971-11-08|
    [返回顶部]